Single-drug versus combination empirical therapy for gram-negative bacillary infections in febrile cancer patients with and without granulocytopenia.

AUTOR(ES)

Piccart, M

RESUMO

Empirical therapy with cefoperazone was compared with cefoperazone plus amikacin in granulocytopenic and nongranulocytopenic febrile patients. In nonneutropenic patients the overall response rate to cefoperazone was 88%; 10 of 12 gram-negative bacteremic patients were cured. Cefoperazone plus amikacin resulted in an 88% overall response rate and cured 14 of 15 patients with bacteremia. In neutropenic patients the overall response rate was 77% with cefoperazone alone and 73% with cefoperazone plus amikacin; the cure rates for gram-negative bacteremias were 8 of 11 and 6 of 12 patients, respectively. Our findings support the concept of single-drug empirical therapy with cefoperazone in febrile cancer patients, whether granulocytopenic or not, especially when gram-negative bacteremias are predominantly caused by Escherichia coli or Klebsiella species. The issue of Pseudomonas spp. and other more resistant pathogens needs further assessment with a larger number of patients.

Documentos Relacionados

• Ceftazidime as single-agent therapy for gram-negative aerobic bacillary osteomyelitis.
• Monotherapy versus beta-lactam-aminoglycoside combination therapy for gram-negative bacteremia.
• Pharmacokinetics of aztreonam in patients with gram-negative infections.
• Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections.
• Correlation of aminoglycoside dosages with serum concentrations during therapy of serious gram-negative bacillary disease.